Medytox’s Cholic Acid Fat-Reduction Injectable Nuviju Surpasses 30,000 Vials in Cumulative Supply
Medytox announced on Sept. 18 that cumulative supply of Nuviju , the world’s first fat-reduction injectable formulated with cholic acid , has...
Search results for "drug treatment"
Yuhan Outlines Clinical Progress for Oral Targeted Anticancer Candidate YH42946 at WCLC 2026
Yuhan Corporation has detailed the status and trial design of the ongoing Phase 1/2 clinical study for YH42946, an oral targeted anticancer candidate...
To Curb GLP-1 Misuse, Experts Urge Tracking Who Gets Prescribed Wegovy and Mounjaro—and Why
As the adoption of GLP-1 receptor agonist obesity medications such as Wegovy and Mounjaro accelerates, medical experts...
Beyond Cosmetics: Foreign Tourists Stock Up on Korean OTC Skin Ointments
Search TikTok for "must-buy items at Korean pharmacies," and a steady stream of video recommendations fills the screen.
GC Pharma’s Homegrown mRNA Vaccine Advances to Phase 2 Trials
GC Pharma announced on the 11th that South Korea’s Ministry of Food and Drug Safety has approved its Phase 2 clinical...
Gachon University Gil Medical Center Recruits Renowned Allergy Specialist Choi Dong-chul
Gachon University Gil Medical Center has appointed Prof. Choi Dong-chul, a leading expert in severe allergies and...
Restless Legs at Bedtime? The Overlooked Sleep Disorder Affecting 1 in 20 People
〈Editor’s note〉 Restless legs syndrome is a surprisingly common condition, yet it is frequently misdiagnosed as muscle...
“I Dream of an Ordinary Life”: Expanded Insurance Coverage Brings New Hope to Dravet Syndrome Families
“Until just before my daughter turned 2, she frequently suffered not only febrile seizures but also afebrile seizures.
Celltrion Files Phase 4 IND with FDA to Support 240 mg High-Dose Zymfentra Regimen in US
Celltrion has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for a Phase 4...
Samsung Biologics to Raise ₩3 Trillion in Rights Offering to Fund ₩2.7 Trillion Acquisition of PolyPeptide Group
Samsung Biologics is proceeding with a 3 trillion won ($2.25 billion) rights offering, directing approximately 90% of...